Zhitong Finance App News, Yinnuo Pharmaceutical-B (02591.HK) announced that on July 27, 2026, the Group's two commissioned production sites for the espagrutide alpha injection project in China (both owned and operated by independent third parties) have passed the Good Manufacturing Practice (GMP) compliance inspection carried out by Brazil's National Health Supervision Administration (ANVISA) in accordance with the Drug Inspection Cooperation Program (PIC/S) GMP standards, and ANVISA has issued relevant GMP certificates.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.